News Focus
News Focus
Followers 276
Posts 25995
Boards Moderated 6
Alias Born 01/27/2009

Re: e-ore post# 278

Saturday, 06/08/2013 9:13:31 AM

Saturday, June 08, 2013 9:13:31 AM

Post# of 3177
ASNB - I've mentioned many times the connection ASNB has to the "Powerwand" catheter from Access Scientific (ASNB's patented ChronoflexC). Here's why I think the Powerwand will succeed:

"Kink resistance. The POWERWAND catheter is made of ChronoFlex®C—exclusively available on the POWERWAND—which, owing to a proprietary process, makes it virtually kink-free in almost all clinical situations.

"Greater patient satisfaction, due to extended dwell time and blood draw-ability. In a published, peer-reviewed study (JAVA, Spring 2012), patients rated their satisfaction with the device at 98.7%. By comparison, only a minority of patients (42%) reports being satisfied about their experience with other kinds of peripheral IVs."

"Finally, there is the new CMS incentive—under Medicare’s “value-based purchasing” program—to increase patient satisfaction with the inpatient experience. Hospitals showing “better than average” or “most improved” patient satisfaction are eligible for Medicare bonus payments from a pool of $850 million."

Access Scientific, Inc. is Acquired by Endeavour Capital
SAN DIEGO, CA. (November 6, 2012) — Access Scientific, Inc. (ASI), a leading provider of over-wire vascular access technology, announced today that they have completed an acquisition agreement with Endeavour Capital.

"We are very pleased with the traction POWERWAND has seen in the marketplace. The technology has the potential to significantly improve the patient’s hospital experience by requiring a single needlestick for vascular access throughout the length of stay. Endeavour’s investment will allow us to increase our efforts to bring this groundbreaking vascular access technology to the marketplace,” stated Steve Bierman, M.D., CEO of Access Scientific.
“Access Scientific’s products provide clinical differentiation within the vascular access market. We believe the technology is impactful to both clinicians and patients, and we are excited to provide the growth capital necessary to support ASI’s growth and success,” said Mark Dorman, Endeavour Capital Managing Director."

http://www.the-wand.com/pdf/PR-0021_A.pdf

A good read here:
http://www.infectioncontroltoday.com/articles/2013/03/midline-catheters-an-essential-tool-in-clabsi-reduction.aspx

My posts are my opinion. Do not be influenced by anything you read on any message board website unless you can confirm it.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NORD News